Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080113 | 0.91 | PDGFRB (0.52) | MEN1KMT2AMAPK10ALDH1A1MAPT | |
| SCHEMBL23727131 | 0.91 | PDGFRB (0.52) | MEN1KMT2AMAPK10ALDH1A1MAPT | |
| SCHEMBL25656125 | 0.84 | MEN1 (0.57) | MEN1KMT2AMAPK10ALDH1A1MAPT | |
| SCHEMBL25656102 | 0.83 | ENPP1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL25656123 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPK10ALDH1A1MAPT | |
| SCHEMBL25656098 | 0.79 | ENPP1 (0.50) | PDGFRB | |
| SCHEMBL25656122 | 0.76 | MEN1 (0.58) | MEN1KMT2AMAPK10ALDH1A1MAPT | |
| SCHEMBL23727245 | 0.75 | PDGFRB (0.57) | MEN1KMT2AMAPK10ALDH1A1MAPT | |
| SCHEMBL30117272 | 0.74 | ENPP1 (0.59) | MAPTPDGFRB | |
| SCHEMBL23762281 | 0.74 | ENPP1 (0.59) | MAPTPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | MEN1 796/4885KMT2A 4288/4885MAPK10 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.